Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy announced financing of US$21 million in equity and debt financing.
Read also – ABC Impact Secures First Close Of Fund II With Support From New Investors
The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company’s PRT120 oral therapy for peanut allergy.
Read also – Israel-based Xyte Secures $30M Funding
“SPRIM brings valuable expertise, capabilities and an international investment network to Prota’s technology and clinical program,” said Prota Executive Chairman Kelly Constable. “This partnership and funding will accelerate Prota’s drug development plans and clinical trial program, and we look forward to this strategic collaboration as Prota moves toward its Phase 3 trial.”
Read also – Animoca Brands begins Phased launch of ‘Anichess’ in Partnership with Chess.com and Magnus Carlsen
The new investment will advance the chemistry, manufacturing, and controls (CMC), accelerate the path to an Investigational New Drug Application (IND), and expand Prota’s executive management team to bring on board critical expertise in late-stage drug development and commercialization.
Read also – Indonesia-based DayaTani Secures $2.3 Mn Seed Funding
“Our Phase 2b[1] multicenter randomized controlled trial conducted by MCRI showed that PRT120 is highly effective at inducing remission of allergy, and more importantly, leads to significant and clinically meaningful improvement in quality of life, compared with standard care (placebo treatment),” said Prota founder Professor Tang. “Long-term follow-up data further shows that children in remission have fewer reactions, less rescue epinephrine use, and far greater improvement in quality of life than children who are only desensitized, validating remission as the patient-preferred outcome.”
Read also – Wow! Momo Secures Approximately $42 Mn in Series D Round
“The food immunotherapy market is expanding rapidly with a range of therapies currently in early- through late-stage development. We are excited to support Prota in its journey to deliver a solution that can potentially transform the treatment of peanut allergy by releasing patients from the shackles of life-long maintenance dosing and allergen avoidance,” said Michael Shleifer, managing partner and co-founder of SGI, a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries.
Read also – TVM Capital Healthcare Invests in Alina Vision
About SPRIM Global Investments (SGI)
SPRIM Global Investments (SGI) is a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries. SGI invests in biotechnology, digital health and R&D service companies to commercialize the newest technologies and accelerate innovations that are the future of health around the world.
Read also – Goodnotes Acquires Korean AI Startup Dropthebit
About Prota Therapeutics
Prota Therapeutics is an Australian proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments for food allergy. Prota holds intellectual property covering the proprietary food immunotherapy technology developed at the MCRI. The company is, in part, a OneVentures’ Healthcare Fund III investment.
Read also – Hong Kong-based HashKey Group Raises Nearly US $100M Series A Funding
